Results 171 to 180 of about 62,620 (348)

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 4, Page 494-506, February 2026.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas   +18 more
wiley   +1 more source

Coexisting Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Overlapping Challenges in Diagnosis and Treatment

open access: yesCase Reports in Gastroenterology
Introduction: Hepatobiliary overlap syndromes describe the coinciding presentation of more than one immune-mediated biliary and liver disease in a single patient and present complex challenges in diagnosis and treatment.
Hannah W. Fiske   +7 more
doaj   +1 more source

Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis

open access: green, 2016
Sebastian Torben Jendrek   +22 more
openalex   +2 more sources

Soluble CD163 as a Biomarker of Liver Fibrosis and Inflammation in Liver Transplant Recipients

open access: yesClinical Transplantation, Volume 40, Issue 2, February 2026.
ABSTRACT Background and Aims Post liver transplantation (LT) inflammation and fibrosis are clinical challenges that may affect long‐term outcomes. We aimed to investigate sCD163 as a biomarker of liver fibrosis in LT recipients and compare it with the Fibrosis 4 (FIB‐4) score and FibroScan.
Emilie Høegholm Ernst Lauridsen   +7 more
wiley   +1 more source

Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases

open access: yesGastro Hep Advances
Farnesoid X receptor (FXR) agonists have emerged as a promising therapeutic strategy for the management of various gastrointestinal (GI) diseases, including primary biliary cholangitis, nonalcoholic fatty liver disease, inflammatory bowel disease ...
Mohammad Almeqdadi, Fredric D. Gordon
doaj   +1 more source

Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort

open access: yesLiver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background and Aims We investigated the associations between SLD, fibrosis stage, and all‐cause and cause‐specific mortality, with a focus on SLD subtypes. Methods We analysed 486 156 UK Biobank participants. SLD cases were identified using fatty liver index ≥ 60. Causes of death were confirmed via death registries.
Qi Feng   +5 more
wiley   +1 more source

164 A Historical Cohort Study Comparing the Clinical Outcome of Ulcerative Colitis and Crohn's Disease in the Presence of Primary Sclerosing Cholangitis

open access: bronze, 2012
Udayakumar Navaneethan   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy